By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem networks with Asian partners at CPhI Japan
Bubendorf, Switzerland: –Peptide and Oligonucleotide technology specialist Bachem AG will be returning to Asia’s premier pharma trade expo and networking event, CPhI Japan in Tokyo in late April 2022.
Under its ‘Leading Partner in Tides’ banner, the Bachem stand at Booth: 1E-08 in the CPhI zone at Tokyo’s Big Sight Exhibition Center will showcase its ever-expanding portfolio of CMO capabilities, expanding from peptides into oligonucleotide (oligomers) alongside generic APIs and research molecules with GMP manufacturing expertise across the range.
Bachem can thus support the success of client projects from initiation, through all clinical development phases to commercial supply.
Bachem will also contribute to the CPhI conference agenda with Naoki Yamamoto, Bachem’s Head of Business Development & Sales Asia Pacific, delivering a presentation on Day Three (1030 hrs, April 22). Mr. Yamomoto’s presentation, ‘Innovation that transforms lives – oligonucleotide manufacturing at Bachem’ will review the emergence of oligos as a new treatment option in rare and orphan disease areas, and their maturing into a drug class addressing a broad spectrum of indications.
He will show how Bachem’s decades of experience in the development, production and regulatory support of peptides and generic APIs, has allowed it to rapidly establish advanced capabilities in oligonucleotides, further transforming the organization.
As befits an event that has become one a key forum for the Asian pharma market, Bachem will send a strong team to CPhI Tokyo. Supporting Mr. Yamamoto will be Satoshi Mashiko, Head of Business Development for Tokyo-based Bachem K.K., Aya Ito, Business Development Manager and Keiko Nomura, Sales Assistant.
Together they will be dedicated to face-to-face meetings with existing and potential customers from Japan and across Asia.
Bachem has a close relationship with CPhI Japan, having attended the event every year since 2016. It sees the event as a key opportunity to deepen its customers and partner relationships improve its regional brand profile and network with key local thought leaders and opinion formers.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
About CPhI Japan 2022
CPhI Japan is Asia’s second largest pharma expo and one of the most prestigious events on the global pharma industry calendar.
CPhI Japan 2022 will be a three-day physical event opening April 20 at Tokyo’s Big Sight Exhibition Center. Once again, this will now be accompanied by an online virtual platform, CPhI Japan Connect. Together, the two platforms are expected to involve more than 300 exhibiting organizations and 16,000 physical and virtual visitors, representing more than 25 nations.
As before, both the physical and virtual events will incorporate the CPhI expo and six other zoned exhibitions: ICSE for outsourcing solutions, P-MEC (including LabWorld) for machinery and equipment, bioLIVE for biopharma developments, InnoPack for delivery systems and packing, FDF for finished dosage products, and NEX for natural extracts.
The event is organized by Informa and UBM Japan with further information at: https://www.cphi.com/japan/en/home.html
Click on Bachem at CPhI Japan for further information.
Click on Bachem New Chemical Entities (NCEs) to learn more.
Click on Oligonucleotides – Innovation that transforms lives to watch video.
Click on Expanding into Oligos: Interview to watch video.
Subscribe to Bachems Newsletter to receive the latest updates.